Saniona

Business highlights in Q1 2025

• On January 10, Saniona’s Nomination Committee proposed John Haurum as New Chairman of the Board of Directors.
• On January 15, Saniona’s joint venture, Cephagenix, secured seed funding from AdBio Partners and AbbVie ventures, with up to EUR 9 million.
• On February 10, Medix initiated a revision of the tesofensine application based on COFEPRIS’s feedback. Medix now sees a clear path to regulatory approval, and on February 20, Medix resubmitted tesofensine application to COFEPRIS.
• On March 3, Saniona initiated GMP manufacturing and toxicology studies for SAN2355. The objective is to finalize the data package for a clinical trials application by year-end 2025.
• On March 3, Acadia Pharmaceuticals and Saniona announced initial positive results from ACP-711 Phase 1 study.
• On March 10, Saniona appointed Pierandrea Muglia, M.D. as Chief Medical Officer.
• On March 11, Saniona announced that the ongoing research collaboration with Boehringer Ingelheim has been extended with one year.
• In March, Saniona announced the following regarding warrants series TO 4: the exercise price has been determined to SEK 4.88, an agreement on guarantee commitments free of charge is entered, and that Saniona’s board and CEO will exercise 964,334 TO 4 warrants.
• On March 26, Saniona announced initiation of scale-up and manufacturing of toxicology batches for SAN2219.

Significant events after the reporting period

• On April 3, Saniona announced final outcome of exercise of warrants series TO4, corresponding to a total of approximately SEK 115 million before issue costs, which corresponds to 100 percent of the total number of TO 4.
• On May 12, Saniona appointed Johnny Stilou as Chief Financial Officer.

Comments from the CEO
“We’ve entered 2025 with strong momentum – we have restarted all three internal development programs and bolstered our financial position through the successful TO4 financing. With a focused pipeline, a validated business model, and promising regulatory progress on tesofensine, Saniona is now well-positioned to deliver continued value-building in the quarters ahead.”